Skip to content

Feasibility of Videoconference-Based Family Psychoeducation for Young Adult Caregivers of Family Members with Major Depressive Disorder: A Pilot Randomized Controlled Trial

Feasibility of Videoconference-Based Family Psychoeducation for Young Adult Caregivers of Family Members with Major Depressive Disorder: A Pilot Randomized Controlled Trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1032250574
Enrollment
24
Registered
2025-12-17
Start date
2025-12-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Young Adult Caregivers of Family Members with Major Depressive Disorder Young Adult Caregiver, Family Members with Major Depressive Disorder

Interventions

An intervention group receiving 4 sessions and a 1-month follow-up of a videoconference-based family psychoeducation program (40 minutes weekly), and a waitlist control group

Sponsors

Nakamura Hideki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Aged 18 to 39 years 2) Having a family member within the third degree of kinship diagnosed with depression 3) Providing care for a family member with depression. 4) Having sufficient access to and ability to use the internet and a computer or similar device to participate in videoconference-based family psychoeducation.

Exclusion criteria

Exclusion criteria: 1) Currently receiving outpatient treatment for a mental disorder. 2) Having a serious progressive physical illness that is expected to lead to discontinuation of the study. 3) Judged by the principal investigator to be unable to continue participation in the study.

Design outcomes

Primary

MeasureTime frame
The primary outcomes are feasibility measures of the randomized controlled trial, including recruitment rate, program adherence rate, attrition rate, acceptability assessed using the Client Satisfaction Questionnaire (CSQ-8-J), and safety assessed by the occurrence and nature of adverse events.

Secondary

MeasureTime frame
As secondary outcomes, changes in scores from Pre (baseline; week 0) to Post (week 4) and Follow-up (week 8) will be evaluated in the intervention and control groups. Between-group differences will be assessed using HADS, K6, J-ZBI_8, GSES, EQ-5D, and WEMWBS.

Contacts

Public ContactHideki Nakamura

Toho University

hideki.nakamura@med.toho-u.ac.jp+81-3-3762-9881

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026